CD4 and cancer: Recent research shows that targeted TGF-β signaling in CD4+ T cells revives helper T cell responses and suppresses cancer progression, and pharmacological inhibition of TGF-β signaling in helper T cells may define a novel immunotherapy approach targeting the cancer environment in cell and mouse models [39].